Skip to main content
Premium Trial:

Request an Annual Quote

Biognosys Strikes Drug Discovery, Development Deal With Kymera Therapeutics

NEW YORK — Biognosys said on Tuesday that it has signed an agreement to use its proteomics panels to help advance Kymera Therapeutics' drug-discovery and clinical trial efforts.

Kymera is developing small molecules designed to degrade specific proteins in order to treat a range of immune-inflammatory diseases and cancers.

Under the terms of their alliance, the companies will use Biognosys' recently launched TrueSignature platform to monitor and quantify protein degradation associated with Kymera drug candidates. TrueSignature enables the creation of customized panels of up to 100 proteins for pharmacodynamic readouts and clinical biomarker monitoring.

Financial and other terms of the deal were not disclosed.

"Biognosys has been a valued partner as we continue to expand our clinical pipeline across a diverse set of diseases and indications," Kymera Cofounder, President, and CEO Nello Mainolfi said in a statement. "The company's high-precision custom proteomics panels enable us to monitor and quantify protein degradation across all aspects of drug development, including preclinical and clinical programs."

In late 2021, Zurich-based Biognosys expanded an ongoing partnership with Indivumed focused on precision cancer drug discovery.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.